Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis by Maker, G.L. et al.
  
MURDOCH RESEARCH REPOSITORY 
 
 
 
 
This is the author’s final version of the work, as accepted for publication  
following peer review but without the publisher’s layout or pagination.  
The definitive version is available at 
http://dx.doi.org/10.1111/nep.12035  
 
 
Maker, G.L., Siva, B., Batty, K.T, Trengove, R.D., Ferrari, P. and 
Olynyk, J.K. (2013) Pharmacokinetics and safety of deferasirox 
in subjects with chronic kidney disease undergoing 
haemodialysis. Nephrology, 18 (3). pp. 188-193 
 
 
 
http://researchrepository.murdoch.edu.au/13833/ 
 
 
 
 
 
 
Copyright: © 2013 The Authors. 
 
It is posted here for your personal use. No further distribution is permitted. 
 
 
 
Pharmacokinetics and Safety of Deferasirox in Subjects with Chronic Kidney Disease 
Undergoing Haemodialysis 
 
Garth L. Makera,b*, Brian Sivac, Kevin T. Battyd,e, Robert D. Trengoveb,f, Paolo Ferraric  
and John K. Olynykc,e,g,h 
 
aSchool of Biological Sciences and Biotechnology, Murdoch University, Western Australia, 
Australia. 
bMetabolomics Australia, Murdoch University, Western Australia, Australia.  
cFremantle Hospital and Health Service, Western Australia, Australia. 
dSchool of Pharmacy, Curtin University, Western Australia, Australia. 
eCurtin Health Innovation Research Institute, Curtin University of Technology, Western 
Australia, Australia. 
fSeparation Science and Metabolomics Laboratory, Murdoch University, Western Australia, 
Australia. 
gWestern Australian Institute of Medical Research, Western Australia, Australia. 
hInstitute for Immunology and Infectious Diseases, Murdoch University, Western Australia, 
Australia. 
 
*To whom correspondence should be addressed. Dr. Garth Maker, School of Biological 
Sciences and Biotechnology, Murdoch University, Murdoch, WA, 6150, Australia. E-mail: 
G.Maker@murdoch.edu.au 
 
Key words: chronic kidney disease, ferritin, iron overload, chelation, deferasirox 
 
Word count (Introduction): 483 
Word count (Discussion): 605 
 
 2 
Abstract 
Treatment of chronic kidney disease (CKD) includes parenteral iron therapy, and these 
infusions can lead to iron overload. Secondary iron overload is typically treated with iron 
chelators, of which deferasirox is one of the most promising. However, it has not been 
studied in patients with CKD and iron overload. A pilot study was conducted to evaluate the 
pharmacokinetics and safety of deferasirox in 8 haemodialysis-dependent patients, who were 
receiving intravenous iron for treatment of anaemia of CKD. Deferasirox was administered at 
two doses (10 mg/kg and 15 mg/kg), either acute (once daily for two days) or steady-state 
(once daily for two weeks). A dose of 10 mg/kg in either protocol was not sufficient to 
achieve a plasma concentration in the therapeutic range (acute peak 14.1 and steady-state 
22.8 µmol/l), while 15 mg/kg in either protocol maintained plasma concentration well above 
this range (acute peak 216 and steady-state 171 µmol/l). Plasma concentration observed at 15 
mg/kg was well above that expected for this dose (40-50 µmol/l), although no adverse 
clinical events were observed. This study highlights the need to profile drugs such as 
deferasirox in specific patient groups, such as those with CKD and iron overload. 
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Introduction 
Iron is an essential element in the body, forming the core of both haemoglobin and 
myoglobin. A healthy individual will have 4 - 5 g iron in their body, and the 1 - 2 mg lost per 
day is replenished by absorption from the duodenum. Iron levels are regulated, as iron can 
cause significant damage to cells through formation of peroxide radicals1. This can result in 
life-threatening damage to the heart, liver, brain, pancreas and joints2. Iron overload is caused 
by inherited disorders of metabolism or acquired from exogenous administration (e.g. iron 
administration or blood transfusion). The latter often occurs in the setting of haematological 
disorders with ineffective erythropoiesis.  
Chronic kidney disease (CKD) is often associated with anaemia, due to deficient production 
of erythropoietin, and also reduced iron absorption and availability3, 4. This is partly due to 
increased production of hepcidin, the hormone that regulates iron absorption5. The treatment 
for anaemia consists of both parenteral iron supplements and erythropoiesis stimulating 
agents (ESA)6-8, although there is evidence of increased morbidity and mortality and many 
users become resistant to ESA9. Multiple infusions of iron are usually administered10, 11 and 
these can result in overload. Whilst serum iron studies, including ferritin levels, have been 
used to monitor iron toxicity and guide replacement, ferritin can be affected by factors such 
as inflammation and infection1. We have recently shown that serum studies are inadequate for 
guiding iron status in subjects with CKD12. Furthermore, 60% of haemodialysis subjects have 
hepatic iron concentration (HIC) greater than twice normal13. 
Secondary iron overload disorders are usually treated with iron chelation agents. Deferasirox  
is the first oral iron-chelating drug approved for the reduction of chronic iron overload. It has 
a high, specific affinity for iron14, and is effective at multiple doses. In patients over 16 years 
old with β-thalassaemia and transfusional iron overload, a dose of 20 mg/kg/day will 
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maintain plasma levels within the therapeutic range of 15-20 µmol/l (trough) to 60-100 
µmol/l (peak) over 24 hours15. Deferasirox is metabolised through hepatic glucuronidation16, 
which can vary greatly from patient to patient. In many countries, regulatory authorities have 
approved the use of deferasirox in patients with creatinine clearance > 40 ml/min, simply 
because of the lack of safety and pharmacokinetic data. Moreover, the manufacturer’s 
prescribing information warns against the use of deferasirox in patients with impaired renal 
function due to reported cases of acute renal failure. 
There is a pressing need to evaluate efficacy and safety of potential therapies of iron overload 
complicating CKD. Access to accurate measurements of plasma deferasirox levels is limited 
18, 19. The aims of this study were to (1) develop and validate a simple method for the analysis 
of deferasirox in human plasma, and (2) conduct a phase 1 safety study of the administration 
of deferasirox at 10 mg/kg and 15 mg/kg daily in stable subjects undergoing haemodialysis 
for CKD, with monitoring of side effects and plasma deferasirox levels. 
 
Methods 
Study subjects and protocol 
An open label, single arm, phase I pilot study to evaluate the pharmacokinetics and safety of 
deferasirox at 2 dose levels of 10 mg/kg/day and 15 mg/kg/day was conducted in 8 
haemodialysis-dependent patients, who were receiving intravenous iron and erythropoietin 
therapy for treatment of anaemia of CKD. Power analysis determined that with n = 4, we had 
90% power to detect a difference of 15 µmol/l, where a = 0.05 and SD = 5, and 85% power to 
detect a difference of 35 µmol/l, where SD = 15.  
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Subjects were included if they were able to provide written informed consent, aged 18-80 
years, and fulfilled the following criteria: CKD dependent on haemodialysis for at least 2 
years; requirement for intravenous iron and erythropoietin therapy as per the current best 
practice protocol in use at Fremantle Hospital and Health Services; received a minimum of 4 
g total intravenous iron in the 2 years before study entry; transferrin saturation >25%; 
haemoglobin > 110 g/L for the 3 months preceding enrolment; normal or minimally abnormal 
cardiac function (NYHA Class 1, left ventricular ejection fraction ≥ 50% measured by 
echocardiography or nuclear medicine); expected life expectancy > 12 months; no significant 
comorbidity which would preclude deferasirox therapy; pre-menopausal female patients who 
were sexually active must use an effective method of contraception, or must have undergone 
clinically documented total hysterectomy, ovariectomy, or tubal ligation and have a negative 
pregnancy test. 
Exclusion criteria included: significant comorbid conditions which in the opinion of the 
treating nephrologist would preclude inclusion in the study; homozygosity for C282Y 
mutation or compound heterozygosity for C282Y/H63D mutations in HFE gene; active 
gastrointestinal bleeding or other source of blood loss; alanine aminotransferase > 5 x upper 
limit of normal; patients with uncontrolled systemic hypertension; haemolysis or other 
haematological disorder which reduces haemoglobin level; past malignancy with potential to 
influence study outcome; pregnant or breast feeding; patients treated with systemic 
investigational drugs within the past 4 weeks or topical investigational drugs within the past 7 
days; history of non-compliance, or unwilling to comply with the protocol; history of drug or 
alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by 
the laboratory assays conducted during the run-in period; patients with a known history of 
HIV; life expectancy of < 12 months. 
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Four subjects received a daily dose of deferasirox (Exjade) 10 mg/kg administered at 0800 
starting on a pre-dialysis day (Day 1) with repeated sampling for pharmacokinetic studies 
over the next  48 hours covering the rest of the pre-dialysis day and the subsequent dialysis 
day.  Blood was taken at time 0 (pre-dose), 2, 4, 6, 8, 24 (pre-dose), 26, 28, 30, 32 and 48 
(pre-dose) hours for each patient. Each patient then received deferasirox 10 mg/kg/day for a 
further 2 weeks and had pharmacokinetic studies repeated over 48 hours (on Days 15 and 16), 
starting on a non-dialysis day and continuing over the subsequent dialysis day. During the 2-
weeks steady-state study period, erythropoietin and iron were maintained unchanged, and 
dialysis treatment time for all patients was 270 minutes. The study protocol was then repeated 
on four different subjects who received a daily dose of deferasirox 15 mg/kg. The baseline 
characteristics of the study subjects are summarised in Table 1. 
Deferasirox assay 
LC-MS grade methanol (MeOH) and acetonitrile (ACN) were obtained from Honeywell 
Burdick and Jackson (Muskegon, USA). Formic acid was obtained from Sigma-Aldrich (St. 
Louis, USA). Milli-Q water was obtained from an in-lab Milli-Q system (Millipore Corp., 
Billerica, USA). Plasma samples were collected in sterile glass vials and stored at -80ºC. 
Deferasirox and 13C6-deferasirox standards were obtained from Novartis (North Ryde, 
Australia) and Alsachim (Illkirch-Graffenstaden, France) respectively. Due to low solubility 
in water, standards were first dissolved in methanol and subsequently diluted into 95% 
water/5% acetonitrile with 1% formic acid, representing the initial HPLC mobile phase 
composition. Both labelled and unlabelled standards were analysed over the concentration 
range 0.1 to 1000 ng/ml. 
Sample preparation was adapted from the method of Chauzit et al. 19. 100 µl of plasma was 
combined with 100 µl of internal standard solution and diluted 1:9 with dipotassium 
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phosphate buffer (0.1 M, pH 3). This solution was vortexed for 5 seconds to convert the iron 
chelate back to free drug. Acetonitrile was added (300 ml) and vortexed for 30 seconds to 
precipitate proteins. The solution was centrifuged at 13000 g and 20°C for 5 minutes and the 
supernatant was diluted 1:99 with 95% water/5% acetonitrile with 1% formic acid. 
Samples were analysed on a Varian 212-LC with PAL autosampler. The column used was a 
Restek Ultra Aqueous C18 (100 x 2.1 mm, 3 µm). The flow rate was 0.2 ml/min and the 
mobile phase consisted of: A: H2O + 1% formic acid; B: acetonitrile + 1% formic acid. The 
HPLC gradient was as follows (%A:B): 0 min – 95:5; 3 min – 95:5; 10 min – 0:100; 15 min – 
0:100; 17 min – 95:5; 20 min – 95:5. 
The HPLC was coupled to a Varian 325-MS triple quadrupole mass spectrometer with a 
vortex electrospray ionisation source (Agilent Technologies, USA). Drying gas was set at 
300°C and 25 psi, nebulizing gas was set at 70 psi and vortex gas was set at 300°C and 30 
psi. Capillary voltage was set to 140 V in positive ionisation mode and -84 V in negative 
mode; and CID gas (argon) pressure was 2 mTorr. Automated MS/MS breakdown was 
performed on each standard to determine the appropriate transitions for analysis. Six 
transitions, three in positive ion mode and three in negative, were identified for both labelled 
and unlabelled forms of the drug. For the unlabelled drug, the following transitions were 
used: positive m/z 374  108, 136 and 240; negative m/z 372  133, 252 and 328. For the 
labelled drug, the same transitions were used + m/z 6. 
The LC-MS/MS method was validated for the following parameters: selectivity, recovery, 
precision, linearity and sensitivity. Selectivity was determined by analysis of both spiked and 
drug-free plasma to determine the presence of any co-elution from matrix interference. 
Recovery was calculated by spiking deferasirox standard into plasma at the commencement 
and conclusion of sample preparation. Intra-day precision was determined by performing 5 
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replicate injections of deferasirox standard spiked into plasma (5, 50 and 500 ng/ml) and 
calculating a relative standard deviation (%RSD). This was performed over three consecutive 
days to assess inter-day precision. Linearity was determined by plotting a standard curve of 
peak area versus drug concentration over the 0.1 to 500 ng/ml. Sensitivity was determined as 
a limit of detection with a signal-to-noise ration not less than 3:1 and a limit of quantification 
with a ration of not less than 10:1. 
Data analysis 
LC-MS data was analysed using Varian Workstation v. 7 (Agilent Technologies, USA). 
Concentration values below the limit of quantification were set at zero. Non-compartmental 
pharmacokinetic analysis (Kinetica Version 5.0; Thermo Fisher Scientific, Waltham MA, 
USA) was used to determine the area under the plasma concentration-time curve (AUC0-∞), 
the area under the first moment-time curve (AUMC0-∞), mean residence time (MRT), 
apparent clearance at steady state (CL/F = Dose/AUC, where F is bioavailability), apparent 
volume of distribution at steady state (Vss/F = CL × MRT) and the average plasma 
concentration at steady state (Css,av). Peak and trough plasma concentrations were determined 
from the concentration-time data. 
 
Results 
Deferasirox assay 
Both deferasirox and 13C6-deferasirox eluted from the column with a retention time of 8.9 
minutes. Extraction of drug-free plasma showed no interference on any of the twelve MS/MS 
transitions used for labelled and unlabelled drug. Extraction recovery of deferasirox was 
93%. Standard curves for both forms of the drug were linear over the range analysed (r2 = 
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0.99 for both). The limit of detection for both forms of the drug was 0.1 ng/ml and the limit 
of quantification was 0.5 ng/ml. Overall the assay had an intra-day precision of 6.1% RSD, 
with the three concentrations having precision as follows: 5 ng/ml: 5.8%; 50 ng/ml: 9.2%; 
500 ng/ml: 3.2%. The overall inter-day precision was 5.9% RSD, with the three 
concentrations as follows: 5 ng/ml: 4.3%; 50 ng/ml: 3.7%; 500 ng/ml: 9.8%. 
Patient data 
The baseline characteristics of the study subjects are summarised in Table 1, and there were 
no significant differences observed between the two patient groups for any of the parameters 
measured. Mean time on dialysis was substantially higher for patients receiving the 10 mg/kg 
dose (852 ± 128 days) than the 15 mg/kg dose (576 ± 234 days), although this was not 
statistically significant (p = 0.8).  
There was no attrition, and all patients completed the full study. During the course of the 
study, there were no observed adverse clinical or biochemical test parameters on any of the 
study subjects at deferasirox doses of 10 mg/kg or 15 mg/kg daily (Table 2). 
Pharmacokinetic studies of deferasirox 
Pharmacokinetic data is summarised in Table 3. Mean plasma deferasirox concentrations for 
the 10 mg/kg study are shown in Figure 1. Both acute and steady-state treatments show the 
same trend pre- and post-dialysis. For the acute dose, deferasirox peaked at 8.1 (± 5.6) μmol/l 
and the trough was 3.2 (± 1.7) μmol/l. Post-dialysis, the peak and trough deferasirox 
concentrations were 4.1 (± 2.5) μmol/l and 4.1 (± 1.8) μmol/l respectively. The AUC0-∞ for 
the first dose (pre-dialysis) was 154 (± 163) μmol.h/l and the AUC0-∞ for the second dose 
(post-dialysis; adjusted for residual effects from the first dose) was 239 (± 147) μmol.h/l. 
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With a steady-state dose of 10 mg/kg/day, deferasirox peaked at 13.8 (± 9.2) μmol/l and 
dropped to 5.3 (± 2.4) μmol/l at 24 h. Post-dialysis, it peaked at 22.8 (± 4.5) μmol/l and at 48 
h had dropped to 7.9 (± 3.9) μmol/l. The pre-dialysis AUC0-∞, CL/F, Vss/F and Css,av were 
207 (± 168) μmol.h/l, 0.21 (± 0.15) l/h/kg, 2.0 (± 1.2) l/kg and 8.6 (± 7.0) μmol/l respectively. 
The post-dialysis AUC0-∞, CL/F, Vss/F and Css,av were 326 (± 190) μmol.h/l, 0.11 (± 0.06) 
l/h/kg, 0.9 (± 0.4) l/kg and 13.6 (± 7.9) μmol/l respectively. 
Figure 2 shows mean plasma deferasirox concentrations for the 15 mg/kg study. Both acute 
and steady-state treatments show the same trend pre- and post-dialysis. For the acute dose, 
deferasirox peaked at 129.4 (± 62.0) μmol/l and the trough was 18.7 (± 14.0) μmol/l. Post-
dialysis, the peak and trough deferasirox concentrations were 216.2 (± 56.2) μmol/l and 113.0 
(± 80.9) μmol/l respectively. The AUC0-∞ for the first dose (pre-dialysis) was 1589 (± 1676) 
μmol.h/l and the AUC0-∞ for the second dose (post-dialysis; adjusted for residual effects from 
the first dose) was 4814 (± 4800) μmol.h/l. 
With a steady-state dose of 15 mg/kg/day, deferasirox peaked at 165.3 (± 92.3) μmol/l and 
dropped to 73.1 (± 49.5) μmol/l at 24 h. Post-dialysis, it peaked at 170.8 (± 55.9) μmol/l and 
at 48 h had dropped to 87.6 (± 47.0) μmol/l. The pre-dialysis AUC0-∞, CL/F, Vss/F and Css,av 
were 2819 (± 3030) μmol.h/l, 0.03 (± 0.02) l/h/kg, 0.3 (± 0.2) l/kg and 117 (± 126) μmol/l 
respectively. The post-dialysis AUC0-∞, CL/F, Vss/F and Css,av were 2752 (± 2388) μmol.h/l, 
0.02 (± 0.01) l/h/kg, 0.2 (± 0.1) l/kg and 115 (± 99) μmol/l respectively. 
 
Discussion 
This study has evaluated the pharmacokinetics and safety of deferasirox in 8 haemodialysis-
dependent patients receiving intravenous iron for treatment of anaemia of CKD. It has also 
presented a new, simple and sensitive assay for deferasirox in plasma samples. Using this 
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method, retention times were stable, justifying the use of 1% formic acid in the mobile phase, 
rather than a more complicated buffer. By taking advantage of the increased sensitivity of 
modern LC-MS systems, samples can be diluted prior to analysis, greatly reducing the 
potential for matrix interference. 
Nisbet-Brown et al. 15 determined that for gap-free chelation coverage, plasma levels of 
deferasirox should be maintained between 15-20 (trough) and 60-100 µmol/l (peak), and used 
a dose of 20 mg/kg to achieve this in adult patients with β-thalassaemia. In this study, a dose 
of 10 mg/kg was insufficient to reach the suggested therapeutic concentrations with either 
acute or steady-state doses, although post-dialysis values for the steady-state doses were 
within this range. Doses of 15 mg/kg (both acute and steady-state) maintained levels within 
or above this range.  
Plasma concentrations observed at a dose of 15 mg/kg, with either protocol, were much 
higher than previously observed in non-hemodialysis patients. Galanello et al. 20 observed 
peak concentrations of 32.3 µmol/l with a single dose of 10 mg/kg and 64.3 µmol/l with a 
single dose of 20 mg/kg in patients with transfusion-dependent β-thalassemia. In contrast to 
the 10 mg/kg study, post-dialysis concentrations for the acute dose were higher than for the 
steady-state dose, which was unexpected. No clear clinical reason for this elevated 
concentration was observed, although much of this variation is due to one patient, who had 
levels approximately 3-fold higher than the other patients (peak 438 µmol/l). This highlights 
the need to evaluate drugs such as deferasirox in specific patient groups in which they are 
being considered, even when the primary method of drug clearance is not expected to be 
altered by underlying disease processes, such as those with CKD and iron overload. 
There are no data pertaining to the ability of deferasirox to be dialysed, however the 
compound binds to albumin (40 g/L) at 98-99% efficiency for deferasirox concentrations 
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between 10 and 105 μg/mL. Deferasirox and its metabolites are primarily excreted in the 
faeces (84% of the dose), and renal excretion of deferasirox and its metabolites is minimal 
(8% of the dose). Thus, it is not anticipated that hemodialysis would significantly affect the 
clearance of the drug. Although pharmacokinetic data in patients without CKD would suggest 
minimal risk of accumulation of deferasirox owing to the minimal urinary excretion, the 
nearly 10-fold increase in AUC for deferasirox at a dose of 15 mg/kg compared to 10 mg/kg 
in our hemodialysis cohort suggests that uraemia may reduce faecal excretion or enhance 
intestinal reabsorption of deferasirox, thus resulting in higher than predicted plasma levels. In 
uremic rats, a decrease in intestinal protein membrane transporters such as P-glycoprotein 
(Pgp) and multidrug-resistance-related protein (MRP2) expression and function secondarily 
to serum uremic factors has been reported 21. This reduction could explain the increased 
bioavailability of drugs such as deferasirox, which is known to be excreted via MRP2 16, in 
renal failure.  
This study has highlighted the need to profile drugs such as deferasirox in patients with 
chronic kidney disease and iron overload. The pharmacokinetics of deferasirox were different 
than expected in these patients, with a small dose incrementation from 10 to 15 mg/kg 
leading to a substantial increase in mean plasma concentration. While no adverse clinical 
parameters were observed in this study, it is clear that further research is needed to avoid 
potential adverse clinical outcomes and evaluate therapeutic efficacy for iron removal. 
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Titles and legends 
 
Figure 1: Mean plasma concentration (±SD) of deferasirox following acute and steady-state 
doses of 10 mg/kg. Dialysis occurred at 24 hours. Acute dose represents a single dose at time 
0. Steady-state doses were 10 mg/kg/day for 2 weeks prior to the study, with deferasirox 
plasma concentrations measured at day 14 and 15. 
 
Figure 2: Mean plasma concentration (±SD) of deferasirox following acute and steady-state 
doses of 15 mg/kg. Dialysis occurred at 24 hours. Acute dose represents a single dose at time 
0. Steady-state doses were 15 mg/kg/day for 2 weeks prior to the study, with deferasirox 
plasma concentrations measured at day 14 and 15. 
 
 
Table 1: Baseline characteristics of the hemodialysis patients undergoing acute deferasirox 
pharmacokinetic studies. 
 
Table 2: Safety characteristics of the 8 hemodialysis patients undergoing steady-state 
pharmacokinetic studies with 2 weeks of daily deferasirox. 
 
 
Table 3: Non-compartmental pharmacokinetic data for deferasirox following steady-state (ss) 
doses of 10 and 15 mg/kg. AUC = area under the plasma concentration-time curve. CL/F = 
apparent clearance at steady state, where F is bioavailability. Vss/F = apparent volume of 
distribution at steady state. Css,av = average plasma concentration at steady state. 
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Table 1 
_________________________________________________________________________________ 
 
Cohort 10 mg/kg 15 mg/kg 
________________________________________________________________________________ 
 
N 4 4 
Age (yr) 68 ± 9 69 ± 5 
Gender (M/F) 3/1 3 /1 
Haemoglobin (g/l) 118 ± 5 127 ± 5 
Transferrin saturation (%) 34 ± 5 34 ± 8 
Ferritin (µg/l) 597 ± 181 553 ± 215 
Time on dialysis (d) 852 ± 128 576 ± 234 
Cumulative Fe dose (mg) 4400 ± 1101 3400 ± 809 
Mean monthly Fe dose (mg) 100 ± 41 150 ± 29 
Weekly erythropoietin dose (u/wk)  8750 ± 5344 10500 ± 4992 
_________________________________________________________________________________ 
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Table 2 
_______________________________________________________________________________ 
 
Cohort Pre-deferasirox Post-deferasirox P-value 
_________________________________________________________________________________ 
 
Haemoglobin (g/l) 122 ± 6 123 ± 11 0.87 
Transferrin saturation (%) 53 ± 20 38 ± 14 0.15 
Ferritin (μg/l) 628 ± 485 559 ± 392 0.91 
Parenteral Fe dose (mg/mt) 150 ± 54 133 ± 81 0.68 
Erythropoietin dose (U/wk)  9330 ± 6020 8330 ± 7090 0.82 
_________________________________________________________________________________ 
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Table 3 
  
10 mg/kg 
 
 
15 mg/kg 
  
Pre-dialysis 
 
 
Post-dialysis 
 
Pre-dialysis 
 
Post-dialysis 
 
 
AUCss (µmol.h/l) 
 
 
207 ± 168 
 
 
326 ± 190 
 
 
2819 ± 3030 
 
 
2752 ± 2388 
 
CL/F (l/h/kg) 
 
0.21 ± 0.15 
 
0.11 ± 0.06 
 
0.03 ± 0.02 
 
0.02 ± 0.01 
 
Vss/F (l/kg) 
 
 
1.9 ± 1.2 
 
0.9 ± 0.4 
 
0.3 ± 0.2 
 
0.2 ± 0.1 
Css,av (µmol/l) 8.6 ± 7.0 13.6 ± 7.9 117.5 ± 126.2 114.7 ± 99.5 
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Figure 1 
 20 
Figure 2 
 
